Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.

5 Dec 2011

Foster children on Medicaid are overly medicated, says report

A study of five states found that foster children are more likely than other kids to be given mind-altering drugs, including antipsychotics and antidepressants.

3 Dec 2011

Government inspectors to lawmakers: More must be done to stop prescription of powerful psych drugs to nursing home patients

Government inspectors told lawmakers Wednesday that Medicare officials need to do more to stop doctors from prescribing powerful psychiatric drugs to nursing home patients with dementia, an unapproved practice that has flourished despite repeated government warnings.

1 Dec 2011

BioLineRx reports third quarter net loss of NIS 7.9 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2011.

29 Nov 2011

Study looks at effects of antipsychotic drugs on two brain receptors linked to schizophrenia

Researchers from Mount Sinai School of Medicine, have identified the pattern of cell signaling induced by antipsychotic drugs in a complex composed of two brain receptors linked to schizophrenia.

24 Nov 2011

Colo. Gov. dismisses GOP call for Medicaid waivers; Fla. sanctions Medicaid docs

Colorado Gov. John Hickenlooper on Thursday rejected a Republican suggestion that he seek a federal waiver to rules governing Medicaid to balance the state budget. The Democratic governor's reaction comes amid a standoff with Republicans over suspending a property-tax break for seniors that costs the state $100 million a year.

19 Nov 2011

Study demonstrates how DISC1 variants affect brain development

Significant progress has been made in understanding the genetic risk factors underlying psychiatric disease. Recent studies have identified common genetic mutations conferring modest risk and rare variants comprising significant risk. One example of a rare cause of psychiatric disorders is the Disrupted in Schizophrenia-1 (DISC1) gene, first identified in a large Scottish pedigree displaying schizophrenia, bipolar disorder and depression.

18 Nov 2011

Psychiatric medication use soaring among women: Report

Attention Deficit Hyperactivity Disorder or ADHD commonly affects boys more than girls. However a new report shows that among adults, the numbers have changed with women’s use of ADHD medications risen over the past decade surpassing that of men.

17 Nov 2011

Combination of antipsychotic and antidepressant drugs may increase risk of CV mortality

People taking anti-psychotic drugs and anti-depressant drugs have a much higher risk of dying during an acute coronary event of a fatal arrhythmia than the rest of the population, finds a Finnish study published in the European Heart Journal.

16 Nov 2011

Delirium may increase risk of death in elderly hospital patients

Hospital patients over 65 who are referred for a psychiatric consultation and found to have delirium are more likely than those without delirium to die within one year following diagnosis, according to a new study published in the journal General Hospital Psychiatry.

11 Nov 2011

Patients with Parkinson's may have increased risk of leg motor restlessness

People with Parkinson's disease may be more likely to have a movement disorder called leg motor restlessness, but not true restless legs syndrome as previous studies have suggested, according to a study published in the November 9, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

10 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

National award encourages bio-science student researchers

A key challenge for the bio-sciences sector is to keep its best research graduates in science and in Australia. The national student awards recognise and encourage promising research students and raise awareness of biosciences research translation and applications.

17 Oct 2011

Awards showcase Australia’s promising future in bio-sciences

The six state winners of the AusBiotech/GSK Student Excellence Awards, announced today, will next week compete for the national biosciences research award at AusBiotech 2011.

10 Oct 2011

UCLA scientists create mouse model for autism

UCLA scientists have created a mouse model for autism that opens a window into the biological mechanisms that underlie the disease and offers a promising way to test new treatment approaches.

30 Sep 2011

New report finds little evidence to support off-label use of atypical antipsychotics

There is little evidence to support the use of atypical antipsychotic drugs for some treatments other than their officially approved purposes, even though many clinicians continue to commonly prescribe these drugs for so-called "off label" uses, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality.

29 Sep 2011

Benefits and harms vary among atypical antipsychotics for off-label use

A review of previous studies suggests that even though atypical antipsychotic medications are commonly used for off-label conditions such as behavioral symptoms of dementia, anxiety, and obsessive-compulsive disorder, these medications are effective for only a few off-label conditions, and that the benefits and harms of these medications for these uses vary, according to an article in the September 28 issue of JAMA.

28 Sep 2011

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

BioLineRx, a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE study of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented at the 3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany.

28 Sep 2011